Group 1: Market Overview - The Hong Kong stock market experienced fluctuations, with the Hang Seng Index closing at 23,831 points, down 145 points or 0.61% [1] - The market turnover decreased to 82.799 billion, with net inflows of 484 million from the Stock Connect [1] - The major indices in the US stock market collectively fell, with the S&P 500 index dropping nearly 1% and the Nasdaq down over 1% [2] Group 2: Sector Performance - In the Hong Kong market, local real estate, software, and 5G concept sectors saw significant declines, while gold stocks performed well [1] - The technology sector remains a core focus for future growth, particularly in AI applications and semiconductor industries, which are expected to benefit from government policies supporting technological self-reliance [3] Group 3: Company Highlights - CSPC Pharmaceutical Group saw an 8.1% increase in stock price after receiving a drug registration approval for a new product, which is expected to enhance its product line and drive performance growth [1] - China Railway Group, a recommended stock, experienced an 11.0% increase last week, indicating a potential opportunity for investors [3] - The report suggests continued attention on leading companies in the semiconductor industry, such as Hua Hong Semiconductor and SMIC, which are expected to benefit from domestic policy support [9]

Major Events - Singularity Guofeng (01280) sold all shares of China Silver Ray (Hong Kong) Investment Holdings Limited at zero cost [1] - ZTE Corporation (00763) plans to invest 117 million yuan to subscribe to Jianxing Zhanlu Fund shares [1] - Cloud Factory (02512) subsidiary won the bid for the second phase of the artificial intelligence industry base project [1] - CSPC Pharmaceutical Group (01093) received drug registration approval for Chlorpheniramine Lactate Injection [1] - Derin Holdings (01709) reported a Bitcoin balance of 84.555 BTC as of January 31 [1] - Baiguoyuan Group (02411) diluted its stake in Baiguoyuan Commercial Management to 51.02%, with core management investing to enhance new business layout [1] Operating Performance - XPeng Motors-W (09868) delivered 20,011 new vehicles in January [1] - Ruipulan Jun (00666) issued a profit warning, expecting a net profit of approximately 630 million to 730 million yuan in 2025, turning from loss to profit [1] - China Merchants Jinling (00978) projected a total contract sales amount of approximately 32.308 billion yuan in 2025, a year-on-year decrease of 23.91% [1] - China National Building Material (03323) issued a profit warning, expecting a shareholder loss of approximately 2.3 billion to 4 billion yuan in 2025, turning from profit to loss [1]

Core Viewpoint - The announcement highlights that CSPC Pharmaceutical Group has received drug registration approval from the National Medical Products Administration of China for its Lercanidipine injection, which is a rapid-acting intravenous antihypertensive medication designed for patients who cannot take oral medications effectively [1] Group 1: Product Details - The Lercanidipine injection is classified as a dihydropyridine calcium channel blocker and is intended for the treatment of hypertension [1] - The product is available in two formulations: 25mg in a 50ml vial and 50mg in a 100ml vial [1] Group 2: Advantages - The product offers significant advantages over commonly used medications, including faster onset of action and the ability to achieve rapid, real-time, and precise blood pressure control [1] - It is particularly suitable for patients with liver and kidney dysfunction, as dosage adjustments are not required during treatment [1] - The formulation does not require dilution, which can significantly benefit patients at risk of fluid overload [1] Group 3: Market Impact - The approval of this product will enhance CSPC's product pipeline in the cardiovascular disease treatment sector, increasing its competitiveness in this field [1] - The product is expected to address the clinical demand gap for emergency hypertension medications [1]

Core Viewpoint - The approval of Chloride Dihydropyridine Injection by the National Medical Products Administration of China represents a significant advancement for the company in the cardiovascular treatment sector, addressing an unmet clinical need for emergency hypertension medications [1] Company Summary - The product is a dihydropyridine calcium channel blocker, classified as a rapid-acting intravenous antihypertensive drug, suitable for patients who cannot take oral medications or have poor expected responses to oral treatments [1] - The injection comes in two formulations: 50ml with 25mg and 100ml with 50mg [1] - The approval enhances the company's product pipeline in the cardiovascular disease treatment area, increasing its competitiveness in this field [1] Product Advantages - The product offers significant advantages over commonly used clinical medications, including faster onset of action, allowing for rapid, real-time, and precise blood pressure control [1] - It is particularly suitable for patients with liver and kidney dysfunction, as dosage adjustments are not required during treatment [1] - The product does not require dilution or preparation, which can significantly benefit patients at risk of fluid overload [1] Market Implications - The approval is expected to fill a clinical demand gap for emergency hypertension medications, thereby potentially increasing market share and revenue for the company in the cardiovascular sector [1]

Core Viewpoint - The approval of Chloride Dihydropyridine Injection by the National Medical Products Administration of China represents a significant advancement for the company in the treatment of hypertension, particularly for patients who cannot take oral medications [1] Group 1: Product Details - The product is a dihydropyridine calcium channel blocker, classified as a rapid-acting intravenous antihypertensive drug [1] - It is specifically designed for patients who are unsuitable for oral medication or have poor expected outcomes from oral treatments [1] Group 2: Advantages - The injection has notable advantages over commonly used clinical medications, including faster onset of action and the ability to achieve rapid, real-time, and precise blood pressure control [1] - It is particularly suitable for patients with liver and kidney dysfunction, as dosage adjustments are not required during treatment [1] - The product does not require dilution or preparation, which significantly benefits patients at risk of fluid overload [1] Group 3: Market Impact - The approval will enhance the company's product pipeline in the cardiovascular disease treatment sector, increasing its competitiveness in this field [1] - It is expected to address the clinical demand gap for emergency hypertension medications [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 （股份代號：1093） （於香港註冊成立之有限公司） 自願公告 氯維地平乳狀注射液獲藥品註冊批件 石 藥 集 團 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）董 事 會（「 董 事 會 」）欣 然 宣 佈，本集團開發的氯維地平乳狀注射液(50ml: 25 mg、100ml: 50mg)（「該產品」）已獲得中華人 民共和國國家藥品監督管理局頒發的藥品註冊批件。 該產品是二氫吡啶類鈣通道阻滯拮抗劑，屬於速效靜脈降壓藥，適用於治療不適宜口服或 預期口服藥物治療效果不佳的高血壓患者。與臨床常用的治療藥物相比，該產品具有以下 顯 著 優 勢 ： 起 效 更 快 ， 可 實 現 血 壓 的 快 速 、 實 時 、 精 準 調 控 ； 更 適 用 於 肝 腎 功 能 異 常 患 者 ， 其 用 藥 期 間 無 需 調 整 劑 量 ； 使 用 時 無 需 稀 釋 配 製 ...